Bone marrow inflammation in haematological malignancies
Open accessThe DOI matches its Crossref record; 233 of the 238 references it cites were found in a registry or an index.
Abstract
Tissue inflammation is a hallmark of tumour microenvironments. In the bone marrow, tumour-associated inflammation impacts normal niches for haematopoietic progenitor cells and mature immune cells and supports the outgrowth and survival of malignant cells residing in these niche compartments. This Review provides an overview of our current understanding of inflammatory changes in the bone marrow microenvironment of myeloid and lymphoid malignancies, using acute myeloid leukaemia and multiple myeloma as examples and highlights unique and shared features of inflammation in niches for progenitor cells and plasma cells. Importantly, inflammation exerts profoundly different effects on normal bone marrow niches in these malignancies, and we provide context for possible drivers of these divergent effects. We explore the role of tumour cells in inflammatory changes, as well as the role of cellular constituents of normal bone marrow niches, including myeloid cells and stromal cells. Integrating knowledge of disease-specific dynamics of malignancy-associated bone marrow inflammation will provide a necessary framework for future targeting of these processes to improve patient outcome.
Overview
CoChat Summary
TL;DR
This review summarizes how inflammation in the bone marrow microenvironment shapes myeloid and lymphoid haematological malignancies. Using acute myeloid leukaemia and multiple myeloma as examples, it argues that inflammation has disease-specific and sometimes divergent effects on normal bone marrow niches and malignant cell survival.
Key findings
- Bone marrow inflammation is presented as a hallmark of tumour-associated microenvironments that affects niches for haematopoietic progenitor cells and mature immune cells, and supports malignant cell outgrowth and survival.
- The review focuses on inflammatory changes in myeloid and lymphoid malignancies, especially acute myeloid leukaemia and multiple myeloma, and highlights both unique and shared features of inflammation in progenitor-cell and plasma-cell niches.
- The authors state that inflammation exerts “profoundly different effects” on normal bone marrow niches in these malignancies and discuss possible drivers of these divergent effects.
- The review examines contributions from tumour cells, myeloid cells, and stromal cells to inflammatory changes in the bone marrow microenvironment.
Methods
- Narrative review article published in *Nature Reviews Immunology* (2024), not an original experimental study.
- Synthesizes prior literature on bone marrow inflammation in haematological malignancies, using acute myeloid leukaemia and multiple myeloma as illustrative examples.
- Main approach is conceptual synthesis and comparison of disease-specific dynamics of inflammation in normal and malignant bone marrow niches.
Limitations
- Not stated in the paper.
- Evident from the text: this is a review, so it does not report new primary data, sample size, or statistical analysis.
- Evident from the text: the abstract frames conclusions broadly, but the provided text does not specify detailed evidence grading or systematic review methods.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 3 Own results and interpretations
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, inflammation exerts profoundly different effects on normal bone marrow niches in these malignancies”
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the bone marrow, tumour-associated inflammation impacts normal niches for haematopoietic progenitor cells and mature immune cells”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“supports the outgrowth and survival of malignant cells residing in these niche compartments”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 1
Citations
Cites
Items 201–233 of 233
Matthes, T., Manfroi, B., Zeller, A. C., Dunand-Sauthier, I., Bogen, B., & Huard, B. (2015) · Leukemia · doi:10.1038/leu.2015.145 · Cited by 32
BAFF is involved in macrophage-induced bortezomib resistance in myeloma
Chen, J., He, D., Chen, Q., Guo, X., Yang, L., Lin, X., Li, Y., Wu, W., Yang, Y., He, J., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.533 · Cited by 32
Thompson, M. A., Witzig, T. E., Kumar, S. K., Timm, M., Haug, J. L., Fonseca, R., Greipp, P. R., Lust, J. A., & Rajkumar, S. V. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04605.x · Cited by 31
Tsuyama, N., Danjoh, I., Otsuyama, K., Obata, M., Tahara, H., Ohta, T., & Ishikawa, H. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.036 · Cited by 30
Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis
Isidro-Hernández, M., Mayado, A., Casado-García, A., Martínez-Cano, J., Palmi, C., Fazio, G., Órfão, A., Ribera, J., Ribera, J., Zamora, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76206-y · Cited by 30
Pirillo, C., Birch, F., Tissot, F. S., Antón, S. G., Haltalli, M. L. R., Tini, V., Kong, I. Y., Piot, C., Partridge, B., Pospori, C., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021004321 · Cited by 30
Jann, J.-C., Mossner, M., Riabov, V., Altrock, E., Schmitt, N., Flach, J., Xu, Q., Nowak, V., Obländer, J., Palme, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26424-3 · Cited by 29
Plasma cell derived mtDAMPs activate macrophage STING pathway which promotes myeloma progression.
Jibril, A. S., Hellmich, C., Wojtowicz, E. E., Hampton, K., Maynard, R. S., Silva, R. D., Fowler-Shorten, D. J., Mistry, J. J., Moore, J. A., Bowles, K. M., et al. (2023) · Blood · doi:10.1182/blood.2022018711 · Cited by 29
Matrix proteoglycans in tumor inflammation and immunity
Deb, G., Cicala, A., Papadas, A., & Asimakopoulos, F. A. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00023.2022 · Cited by 28
Wiktorin, H. G., Aydin, E., Christenson, K., Issdisai, N., Thorén, F. B., Hellstrand, K., & Martner, A. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1944538 · Cited by 26
Suzuki, T., Morio, T., Tohda, S., et al. (1990) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1990.tb03335.x · Cited by 25
Baron, F., Suciu, S., Amadori, S., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.044347 · Cited by 25
Slavin, T. P., Teh, J. B., Weitzel, J. N., Peng, K., Wong, F. L., Qin, H., Wang, J., Wu, X., Mei, M. G., Pillai, R. K., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.08.013 · Cited by 25
Lubeck, D. P., Danese, M. D., Jennifer, D., et al. (2016) · Blood · doi:10.1182/blood.v128.22.5930.5930 · Cited by 24
Garcia‐Manero, G., Bravo, G. M., Yang, H., Wei, Y., Alvarado, Y., Dinardo, C. D., Daver, N. G., Konopleva, M. Y., Hearn, K. P., Miller, R. M., et al. (2016) · Blood · doi:10.1182/blood.v128.22.227.227 · Cited by 23
Wang, Y., Sun, X., Yuan, S., Hou, S., Guo, T., Chu, Y., Pang, T., Luo, H. R., Yuan, W., & Wang, X. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.01.001 · Cited by 23
Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma
Gallou, S. L., Lhomme, F., Irish, J. M., Mingam, A., Pangault, C., Monvoisin, C., Ferrant, J., Azzaoui, I., Delphine Rossille, A., Bouabdallah, K. K., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.755623 · Cited by 22
Host-related immunodeficiency in the development of multiple myeloma
Dosani, T., Mailankody, S., Korde, N., Manasanch, E. E., Bhutani, M., Tageja, N., Roschewski, M. J., Kwok, M., Kazandjian, D. G., Costello, R., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1361026 · Cited by 20
Damasceno, D., Almeida, J., Teodósio, C., Sanoja-Flores, L., Mayado, A., Pérez‐Pons, A., Puig, N., Arana, P., Paiva, B., Solano, F., et al. (2021) · Cancers · doi:10.3390/cancers13061454 · Cited by 20
Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML)
Zeidner, J. F., & Foster, M. C. (2015) · Current Drug Targets · doi:10.2174/1389450116666150304104315 · Cited by 19
Gamlen, H. A., Romer-Seibert, J. S., Lawler, M. E., Versace, A. M., Goetz, M. L., Feng, Y., Guryanova, O. A., Palmisiano, N. D., & Meyer, S. E. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1598 · Cited by 19
Jaeger, A., Gambheer, S. M. M., Sun, X., et al. (2023) · Blood · doi:10.1182/blood.2022015653 · Cited by 16
S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Lin, C., Garcia-Gerique, L., Bonner, E. E., Mastio, J., Rosenwasser, M. J., Cruz, Z., Lawler, M. E., Bernabei, L. L., Muthumani, K., Liu, Q., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0368 · Cited by 16
Vià, M. D., Lionetti, M., Marella, A., Matera, A., Travaglino, E., Signaroldi, E., Galbussera, A. A., Lucca, U., Mandelli, S., Riva, E., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006498 · Cited by 13
Garcia‐Manero, G., Ademà, V., Urrutia, S., et al. (2022) · Blood · doi:10.1182/blood-2022-167703 · Cited by 11
Myeloid cells promote interferon signaling-associated deterioration of the hematopoietic system
Feyen, J., Ping, Z., Chen, L., van Dijk, C., van Tienhoven, T. V. D., van Strien, P. M. H., Hoogenboezem, R. M., Wevers, M. J. W., Sanders, M. A., Touw, I. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35318-x · Cited by 11
Self-citationChen, H., Sanchez, E., Li, M., Wang, C., Gillespie, A., Shvartsur, A., Vardanyan, S., Harutyunyan, N. M., Garzio, G., Tang, G., et al. (2014) · Blood · doi:10.1182/blood.v124.21.4106.4106 · Cited by 10
Bone marrow eosinophils in plasma cell disorders
Wichert, S., Pettersson, Å., Hellmark, T., Johansson, Å., & Hansson, M. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.06.288 · Cited by 7
Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia
Tobler, A., Moser, B., Dewald, B., et al. (1993) · Blood · doi:10.1182/blood.v82.8.2517.bloodjournal8282517 · Cited by 7
Predictive Value Analysis of Serum Ig A, Ig G, and TNF-α in Recurrence of Multiple Myeloma
Jia, X., Liu, X., & Yang, W. (2022) · Disease Markers · doi:10.1155/2022/2095696 · Cited by 4
Goselink, H. M., Willemze, R., & Falkenburg, J. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(00)00305-2 · Cited by 3
Baila, L., Suciu, S., Muus, P., et al. (2007) · Blood · doi:10.1182/blood.v110.11.1456.1456 · Cited by 2
Nonclassical monocytes are prone to migrate into tumor in diffuse large B-cell lymphomaPreprint
Gallou, S. L., Lhomme, F., Irish, J. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.10.439292 · Cited by 2
Cited by
The role of the haematopoietic stem cell niche in development and ageing
Cain, T. L., Derecka, M., & McKinney‐Freeman, S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00770-8 · Cited by 85
New horizons in our understanding of precursor multiple myeloma and early interception
dos Santos, D. M. C., Toenges, R., Bertamini, L., Alberge, J.-B., & Ghobrial, I. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00755-x · Cited by 36
“The ECM comprises fibrous proteins, proteoglycans and glycosaminoglycans, whereas the soluble factors include a broader range of molecules such as chemokines, cytokines, growth factors, exosomes, nutrients and oxygen.”
Lutz, R., Poos, A. M., Solé-Boldo, L., John, L., Wagner, J., Prokoph, N., Baertsch, M. A., Vonficht, D., Palit, S., Brobeil, A., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adp6667 · Cited by 25
Blanquart, E., Ekren, R., Rigaud, B., Joubert, M.-V., Baylot, V., Daunes, H., Cuisinier, M., Villard, M., Carrié, N., Mazzotti, C., et al. (2024) · Blood · doi:10.1182/blood.2023023529 · Cited by 29
Lim, J. J., Vining, K. H., Mooney, D. J., & Blencowe, B. J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404146121 · Cited by 16
Metadata
- Authors
- de Jong, M. M. E., Chen, L., Raaijmakers, M. H. G. P., & Cupedo, T.
- Affiliations
- Erasmus MC Cancer Institute (NL)
- Corresponding author
- Cupedo, Tom
- Venue
- Nature reviews. Immunology
- Published
- 2024-03-15
- Volume
- 24
- Issue
- 8
- Pages
- 543-558
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W4392864858
- Semantic Scholar
- 8eec83c2a7c101d4a5f7a8e938c4a09b89c96da5
- Cited by
- 54
- References
- 238
- Citations by year
- 2026: 27 · 2025: 20 · 2024: 7
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- other-oa
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Funders
- KWF Kankerbestrijding (11092)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- bone marrow inflammation, tumour-associated inflammation, tumor microenvironment, hematologic malignancies, acute myeloid leukemia, multiple myeloma, myeloid cells, stromal cells, myeloid neoplasms, lymphoid malignancies
- MeSH terms
- Animals, Bone Marrow, Hematopoietic Stem Cells, Humans, Inflammation, Multiple Myeloma, Hematologic Neoplasms, Stem Cell Niche, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.